Only a united EU can tackle cancer
This article was originally published in Scrip
Executive Summary
A call by the European Parliament's Committee on the Environment, Public Health and Food Safety (ENVI) for EU member states to focus more on prevention in the fight against cancer is a laudable, if predictable, step in the right direction. With more than 3 million new cases each year and 1.7 million deaths in the EU, the struggle to contain the disease must be intensified. However, despite much goodwill and concerted action, the battle against cancer in the EU is hampered by two main elements: the legislative process and the fact that the provision of healthcare remains within the competence of the individual member states.
You may also be interested in...
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.
EMA Acts To Freeze GVK Drugs, Guard Against Shortages
The EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.
EMA Acts To Freeze Drugs Linked to GVK Bio, Guards Against Shortages
EMA has recommended suspension of some 700 drug formations linked with Indian clinical trials company GVK Biosciences, but assures national agencies that this won’t result in shortages or safety issues.